“Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma” (2009) Hematology Meeting Reports (formerly Haematologica Reports), 2(5). doi:10.4081/hmr.v2i5.736.